Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Moodys
Dow
Express Scripts

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

LOVENOX (PRESERVATIVE FREE) Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Lovenox (preservative Free) patents expire, and what generic alternatives are available?

Lovenox (preservative Free) is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in LOVENOX (PRESERVATIVE FREE) is enoxaparin sodium. There are thirteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the enoxaparin sodium profile page.

Summary for LOVENOX (PRESERVATIVE FREE)
Drug patent expirations by year for LOVENOX (PRESERVATIVE FREE)
Pharmacology for LOVENOX (PRESERVATIVE FREE)
Paragraph IV (Patent) Challenges for LOVENOX (PRESERVATIVE FREE)
Tradename Dosage Ingredient NDA Submissiondate
LOVENOX (PRESERVATIVE FREE) INJECTABLE;SUBCUTANEOUS enoxaparin sodium 020164 2006-12-07
LOVENOX INJECTABLE;INTRAVENOUS, SUBCUTANEOUS enoxaparin sodium 020164 2006-12-07

US Patents and Regulatory Information for LOVENOX (PRESERVATIVE FREE)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-001 Mar 29, 1993 AP RX Yes No   Start Trial   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-007 Jun 2, 2000 AP RX Yes No   Start Trial   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-004 Mar 27, 1998 AP RX Yes No   Start Trial   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-008 Jun 2, 2000 AP RX Yes No   Start Trial   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-002 Jan 30, 1998 AP RX Yes No   Start Trial   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-003 Mar 27, 1998 AP RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LOVENOX (PRESERVATIVE FREE)

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-006 Jun 2, 2000   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-006 Jun 2, 2000   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-002 Jan 30, 1998   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-005 Mar 27, 1998   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-004 Mar 27, 1998   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-003 Mar 27, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Dow
Harvard Business School
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.